Trials / Completed
CompletedNCT00127127
A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)
A Phase I Clinical Study of L-001079038 in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vorinostat | vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration |
Timeline
- Start date
- 2005-06-10
- Primary completion
- 2009-08-21
- Completion
- 2009-08-21
- First posted
- 2005-08-05
- Last updated
- 2022-09-13
- Results posted
- 2022-05-02
Source: ClinicalTrials.gov record NCT00127127. Inclusion in this directory is not an endorsement.